Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
SEC Accession No. 0002052113-25-002476
Filing Date
2025-07-16
Accepted
2025-07-16 19:02:16
Documents
3

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13G/A  
1 primary_doc.xml SCHEDULE 13G/A 5681
2 EXHIBIT 24: POWER OF ATTORNEY PowerOfAttorney.txt EX-24 2796
3 EXHIBIT 99: ITEM 7 Item_7.txt EX-99 645
  Complete submission text file 0002052113-25-002476.txt   11095
Mailing Address 221 CRESCENT ST. BUILDING 17, SUITE 102B WALTHAM MA 02453
Business Address 221 CRESCENT ST. BUILDING 17, SUITE 102B WALTHAM MA 02453 650-394-5230
Apogee Therapeutics, Inc. (Subject) CIK: 0001974640 (see all company filings)

EIN.: 934958665 | Fiscal Year End: 1231
Type: SCHEDULE 13G/A | Act: 34 | File No.: 005-94122 | Film No.: 251128427
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)

Mailing Address 50 HUDSON YARDS NEW YORK NY 10001
Business Address 50 HUDSON YARDS NEW YORK NY 10001 (212) 810-5800
BlackRock, Inc. (Filed by) CIK: 0002012383 (see all company filings)

EIN.: 991116001 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G/A
SIC: 6211 Security Brokers, Dealers & Flotation Companies
(CF Office: 02 Finance)